

### **Board of Commissioners Meeting**

June 23, 2022 Summit Pacific Medical Center

Gravs HarborCounty Public Hospital District No.1

### Agenda

- 1. 6:00 Call to Order
  - a. Introductions as needed
  - b. Business from audience
- 2. 6:05 Consent Agenda See separate Consent Agenda Action (vote)
- 3. 6:08- Approval of Minutes Action (vote)
- 4. 6:10 Patient Story Lauri Bolton Info
- 5. 6:15 Welcome New Leaders! Josh Martin Info
- 6. 6:20 Nurse Preceptor Program Becky Blackhawk Peterson Info
- 7. Executive Reports
  - a. 6:35 Quality Report and Dashboard, Tori Bernier Info
  - b. **6:50** Finance Report, James Hansen *Info*
  - c. 7:05 Advocacy Committee, Josh Martin (as needed)
  - d. 7:10 Executive Report, Josh Martin Info
- 8. Commissioner Business
  - a. 7:30 Medical Staff Privileges Action (vote)
  - b. 7:35 Resolution 2022-05 The Rural Collaborative Interlocal Agreement Action (vote)
  - c. 7:40 Letter to Representative Chapman Info
  - d. 7:45 Board Retreat Agenda Review Info
  - e. 7:50 Hot Topic Discussion Supreme Court Rules Unanimously
  - f. in Favor of AHA, Others in 340B Case Info
  - q. 8:00 Upcoming Events, Andrew Hooper
  - h. 8:05 Meeting Evaluation, Andrew Hooper
- **9. 8:10 Adjourn** *Action (vote)*

<u>Upcoming events</u>: - BOLD events indicate desired Commissioner attendance.

- Ride the Harbor | McCleary, WA | June 25, 2022
- > Annual Strategic Planning | Union, WA | August 1-3



### **Board of Commissioners Meeting**

June 23, 2022 Summit Pacific Medical Center

Gravs HarborCounty Public Hospital District No.1

#### **Consent Agenda**

A very useful technique involves the use of a consent agenda. The board agenda planners (usually the executive or governance committee, but occasionally the board chair with the CEO) divide agenda issues into two groups of items. The first are those items that must be acted on because of legal, regulatory, or other requirements, but are not significant enough to warrant discussion by the full board. Such issues are combined into a single section of the board agenda book; members review these materials prior to the meeting, and if no one has any questions or concerns, the entire block of issues is approved with one board vote and no discussion. This frees up a tremendous amount of time that would otherwise be squandered on minor issues. Any member can request that an item be removed from the consent agenda and discussed by the full board. The success of the consent agenda is predicated upon all board members reading the material in the consent agenda section of the board agenda book. If they do not, then the board becomes a veritable rubber stamp. The second group of agenda items are those important issues that require discussion, deliberation, and action by the board. These are addressed one by one.

#### **Executive Session Justification**

Executive Session is convened to discuss the following topics, as permitted by the cited sections of the Revised Code of Washington (RCW):

- Executive session (RCW 42.30.110)
  - a. (a) national security
  - b. (b) (c)real estate
  - c. (d) negotiations of publicly bid contracts
  - d. (e) export trading
  - e. (f) complaints against public officers/employees
  - f. (g) qualifications of applicant or review performance of public employee/elective office
  - g. (h) evaluate qualifications of candidate for appointment to elective office
  - n. (i) discuss claims with legal counsel
    - i. existing or reasonably expected litigation
    - ii. litigation or legal risks expected to result in adverse legal or financial consequences
    - iii. presence of legal counsel alone does not justify executive session
  - i. QI/peer review committee documents and discussions
- · Final action must be in open meeting



# For the Period:

# May 2022

Description	Amount
Payroll	\$ 1,908,963
A/P Operations	\$ 3,774,190
A/P Construction	\$ -
Community Care	\$ 150,402
Bad Debt	\$ 460,792
Property Tax Credit	\$ 2,349
Total	\$ 6,296,696



May 26, 2022

AGENDA	DISCUSSION/CONCLUSIONS	ACTIONS/FOLLOW-UP
CALL TO ORDER	CALL TO ORDER	
	The meeting of the Board of Commissioners of the Grays Harbor County Public Hospital	
	District No. 1 was called to order by Andrew Hooper at 6:01 pm	
	Commissioners present: Andrew Hooper, Gary Thumser, Carolyn Wescott, Georgette Hiles,	
	Kevin Bossard	Commissioner Wescott made a
		motion to approve the Consent
		Agenda. Commissioner Hiles
	Present: Josh Martin, Blake Rose, James Hansen, Dr. Ken Dietrich, Lauri Bolton, Jori Stott,	seconded the motion. All voted
	Lourdes Schoch (phone), Wendy Stirnkorb (phone), Joy Borkholder (phone), Rachel Brown (phone)	in favor.
BUSINESS FROM	Business from Audience	
AUDIENCE	NA	
APPROVAL OF		Commissioner Thumser made a
MINUTES		motion to approve the minutes.
		Commissioner Bossard
		seconded the motion. All voted in favor.
PATIENT STORY	CXO Bolton shared thank you note to GI Program and patient experience utilizing	m javor.
	our campus trails (see letter for more details)	
EPIC PRESENTATION	CAO Rose and Tracy Kately, IT Director gave a presentation on the EPIC go live	
	implementation plan (see presentation for more details).	
	<ul> <li>All previous medical archives will be searchable in EPIC with searchable fields.</li> </ul>	
	Discussion regarding dress rehearsals planned for the EPIC go live to ensure systems	
	will work before seeing patients.	
QUALITY	<ul> <li>The patient portal will switch to MyChart.</li> <li>CMO Dietrich shared that Quality Report and Dashboard was postponed due to our</li> </ul>	
QUALITY	annual accreditation survey arriving the day of the regular scheduled Quality	
	meeting.	
	<ul> <li>Overall, the survey was successful. Our first visit we had 14 non-compliant findings.</li> </ul>	
	By this visit we had 12 of those fixed and 7 new level one findings which need to be	
	responded to in 60 days.	
	CMS accepted the EMTALA complaint. The plan will be completed by June 2022.	
FINANCE	<ul> <li>CFO Hansen presented the Finance Report (see report for more details).</li> </ul>	



May 26, 2022

	11
	<ul> <li>Summit Pacific is officially paying cost that was previously supported by FEMA for traveling staff.</li> <li>Days in AR are improving from last month and will continue to move in the right direction.</li> <li>Days cash on hand is decreasing because of expenses going up due to FEMA staffing funds going away.</li> <li>ED Visits continue to exceed budgeted volumes.</li> <li>Summit Pacific does not do a flex budget. Summit does regularly update forecasts</li> </ul>
	<ul> <li>and always seeks to understand variances to the budget.</li> <li>Summit Pacific is still pursuing FEMA dollars to help support the organization through COVID.</li> </ul>
ADVOCACY	<ul> <li>The next Advocacy Committee is scheduled for June.</li> <li>Legislative District 24 CEOs will be meeting tomorrow to review the legislative session with WSHA.</li> <li>Chairman Hooper is on governing board committee and was asked to present on what Summit's advocacy committee.</li> </ul>
EXECUTIVE SUMMARY	<ul> <li>CEO Martin reviewed the Executive Report (see report for more details).</li> <li>CXO Bolton provided an update on Hospital Week.</li> <li>CAO Rose shared patients can now request appointments through the portal.</li> <li>The Master Facility Plan is moving forward with selection of an architect. Four final architects will come back with answers to targeted questions.</li> <li>The funding plan is moving forward for the Master Facility Plan. Strowdwater LLP is helping guide Summit through the funding process for the expansion. Roy Koegen formerly with Kutak Rock will be helping us with securing bonds.</li> <li>USDA will be onsite June 16<sup>th</sup>.</li> <li>CFO Hansen will provide an MFP funding timeline at the next board meeting.</li> <li>CMO Dietrich provided an update on the rise of COVID volumes.</li> <li>Grays Harbor County has to expand public health board to include 3 non-elected officials on the board per new state legislation</li> <li>CEO Martin provided an update on preliminary plans for adult soccer league</li> <li>CEO Martin shared that the Annual Golf Tournament raised a record gross of \$100,000 dollars.</li> <li>CMO Dietrich provided an update on Medicare Annual Wellness visits.</li> </ul>



May 26, 2022

	May 26, 2022	
	<ul> <li>CEO Martin shared that CXO Bolton will be transitioning the end of June and has</li> </ul>	
	agreed to stay on as aper diem employee to support HR. Thank you Lauri for your	
	many years of service!	
COMMISSIONER	Medical Staff Privileges	Commissioner Hiles made
BUSINESS	<ul> <li>Robert Taber, MD – Emergency Medicine – Initial Appointment</li> </ul>	motion to approve the Medica
	<ul> <li>Kevin Caserta, MD – Physiatry – Initial Appointment</li> </ul>	Staff privileges. Commissioner
	<ul> <li>Elizabeth Walz, MD – Neurology – Initial Appointment</li> </ul>	Thumser seconded the motion
	<ul> <li>Robert Apland, DO – Radiology – Initial Appointment</li> </ul>	All voted in favor.
	<ul> <li>Christopher Krol, MD – Radiology - Reappointment</li> </ul>	
	<ul> <li>Ross Ondersma, MD – Radiology - Reappointment</li> </ul>	
	<ul> <li>Brandt Mohr, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>John McGowan, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>John Edwards, MD – Radiology - Reappointment</li> </ul>	
	<ul> <li>Garland McQuinn, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Alan Chan, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Phillip Lowe, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Alice Josafat, MD – Radiology - Reappointment</li> </ul>	
	<ul> <li>David Atkins, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Navneet Singha, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Yasmin Akbari, MD – Radiology – Reappointment</li> </ul>	
	<ul> <li>Madison Creel, SLP (Speech Language Pathologist) – Speech Pathology – Initial</li> </ul>	
	Appointment	
	TRC Resolution	
	<ul> <li>CEO Martin shared an update on the TRC proposed resolution to help formalize an</li> </ul>	
	LLP to help diversify funds for members.	
	<ul> <li>Discussion regarding the risk and responsibility of the hospital members for this</li> </ul>	
	endeavor.	
	<ul> <li>The resolution will be brought forward at the June 2022 Board meeting.</li> </ul>	
	Upcoming Events, Andrew Hooper	
	<ul> <li>Chairman Hooper reviewed upcoming events</li> </ul>	
	<ul> <li>Volunteers are still needed for the Ride the Harbor event.</li> </ul>	
	<ul> <li>Each Board member was requested to bring a topic of interest to include for this year's board education.</li> </ul>	



May 26, 2022

	<ul> <li>Urgent Care wait times were turned off because people were self-selecting to the ED for COVID testing, and creating a dissatisfier for patients.</li> <li>Meeting Evaluation, Andrew Hooper</li> </ul>	
	<ul> <li>Chairman Hooper facilitated meeting evaluation.</li> <li>There were no suggestions for hot topic discussions.</li> </ul>	
ADJOURNMENT	The regular session of the Board of Commissioner's meeting adjourned at 8:00 pm.	Commissioner Bossard made a motion to adjourn the meeting. Commissioner Hiles seconded the motion. All voted in favor.

Recording Secretary

Board Secretary

# Financial Highlights – Monthly Dashboard

## Summit Pacific Medical Center Finance Dashboard May 31, 2022

## Key Financial Results used in review of Operational and Financial Performance

Favorable Variance = + Unfavorable Variance = ()

		May	,		Year-to-Date						
	Actual	Budget	Variance	Var%	Month	Actual	Budget	Variance	Var%	YTD	
Gross Operating Revenue	\$ 12,416,336	\$13,469,916	\$ (1,053,580)	(7.8%)		\$ 62,450,961	\$ 57,575,029	\$4,875,932	8.5%		
Total Operating Expenses	\$ 5,043,069	\$ 4,931,133	\$ (111,936)	(2.3%)		\$ 22,890,846	\$ 23,707,330	\$ 816,484	3.4%		
Payment %	43.8%	43.8%	0.0%	0.0%		45.0%	44.8%		0.2%		
EBITDA Margin	10.8%	20.0%		(9.2%)		22.6%	12.6%		10.1%		
Operating Margin	3.3%	12.6%		(9.3%)		15.3%	4.0%		11.3%		
Net Income Margin	6.4%	15.0%		(8.7%)		18.7%	6.8%		11.9%		
Days in AR						52	47	(5)	(9.7%)		
рсон						289	260	29	11.1%		

2022 Income Statement

							2022 income Statement								
SUMMIT PACIFIC				May							Year-to-[	ate	<b>.</b>		
• MEDICAL CENTER •		Actual		Budget		Variance	Var%		Actual		Budget		Variance	Var%	
Gross Operating Revenue															
Medicare Revenue	\$	5,160,471	\$	5,397,313	\$	(236,842)	(4.4%)	\$	24,444,935	\$	22,135,693	\$	2,309,242	10.4%	
Medicaid Revenue	\$	3,462,364	\$	3,893,880	\$	(431,516)	(11.1%)	\$	17,868,328	\$	17,109,344	\$	758,984	4.4%	
Other Revenue	\$	3,793,501	\$	4,178,723	\$	(385,222)	(9.2%)	\$	20,137,698	\$	18,329,992	\$	1,807,706	9.9%	
Total Gross Operating Revenue	\$	12,416,336	\$	13,469,916	\$	(1,053,580)	(7.8%)	\$	62,450,961	\$	57,575,029	\$	4,875,932	8.5%	
Revenue Deductions															
Medicare Contractual	\$	3.506.503	\$	3,540,151	\$	33,648	1.0%	\$	14,570,696	\$	14,270,892	\$	(299,804)	(2.1%)	
Medicaid Contractual	\$	1,787,307	\$	2,237,589	\$	450,281	20.1%		10,132,492	\$	9,773,608	\$	(358,884)	(3.7%)	
Other Contractual	\$	1,093,235	\$		\$	67,466	5.8%		6,315,315	\$	5,059,376	\$	(1,255,939)	(24.8%)	
Bad Debt Expense	\$	367,455	\$		\$	(2,753)	(0.8%)		2,196,092	\$	1,542,323	\$	(653,769)	(42.4%)	
Community Care	\$	150,402	\$		\$	47,749	24.1%	•	790,463	\$	837,978	\$	47,515	5.7%	
Administrative Adjustments	\$	78,784	\$		\$	(6,886)	(9.6%)	,	340,553	\$	304,056	\$	(36,496)	(12.0%)	
Total Revenue Deductions	\$	6,983,686	\$		\$	589,505	7.8%		34,345,611	\$	31,788,233		(2,557,378)	(8.0%)	
Net Patient Revenue	S	5,432,649	\$		\$	(464,075)			28,105,351	·	25,786,797	\$	2,318,554	9.0%	
	Ą	3,432,047	Ą	3,070,723	ų	(404,073)	(7.770)	Ą	20,103,331	ų	23,760,777	ų	2,310,334	7.070	
Other Revenue	•		•		•		0.0~	•		•		•		0.0~	
COVID Relief Income	\$	- 001 047	\$	-	\$	-	0.0%		1 40 4 400	\$	1 221 427	\$	-	0.0%	
Other Operating Income	\$	221,347	\$	266,299	\$	(44,953)	(16.9%)	\$	1,484,692	\$	1,331,497	\$	153,195	11.5%	
Total Other Revenue	\$	221,347	\$	266,299	\$	(44,953)	(16.9%)		1,484,692	\$	1,331,497	\$	153,195	11.5%	
Net Operating Revenue	\$	5,653,996	\$	6,163,024	\$	(509,028)	(8.3%)	\$	29,590,043	\$	27,118,294	\$	2,471,749	9.1%	
Operating Expenses															
Salaries & Wages	\$	2,243,013	\$	2,745,765	\$	502,752	18.3%	\$	11,305,093	\$	13,454,575	\$	2,149,483	16.0%	
Benefits	\$	579,083	\$	707,630	\$	128,547	18.2%	\$	2,952,166	\$	3,466,495	\$	514,329	14.8%	
Professional Fees	\$	195,097	\$	133,526	\$	(61,570)	(46.1%)	\$	404,611	\$	242,536	\$	(162,075)	(66.8%)	
Supplies	\$	317,497	\$	419,779	\$	102,283	24.4%	\$	1,707,108	\$	1,989,276	\$	282,169	14.2%	
Utilities	\$	45,499	\$	43,099	\$	(2,400)	(5.6%)	\$	223,585	\$	214,014	\$	(9,571)	(4.5%)	
Purchased Services	\$	1,300,460	\$	557,295	\$	(743,165)	(133.4%)	\$	4,546,096	\$	2,769,919	\$	(1,776,177)	(64.1%)	
Insurance	\$	27,353	\$	34,905	\$	7,552	21.6%	\$	190,253	\$	174,525	\$	(15,728)	(9.0%)	
Other Expenses	\$	244,452	\$	228,963	\$	(15,489)	(6.8%)	\$	1,307,208	\$	1,139,487	\$	(167,721)	(14.7%)	
Rentals & Leases	\$	90,615	\$	60,170	\$	(30,446)	(50.6%)	\$	254,726	\$	256,502	\$	1,776	0.7%	
Total Operating Expenses	\$	5,043,069	\$	4,931,133	\$	(111,936)	(2.3%)	\$	22,890,846	\$	23,707,330	\$	816,484	3.4%	
EBITDA	\$	610,927	\$	1,231,891	\$	(620,964)	(50.4%)	\$	6,699,197	\$	3,410,964	\$	3,288,233	96.4%	
Interest & Depreciation Expenses	·	•	·		•		` ,	·		•					
Interest	\$	143,856	\$	143,856	\$	(1)	(0.0%)	\$	725,189	\$	725,188	\$	(2)	(0.0%)	
Depreciation	\$	280,845	\$		\$	32,804	10.5%		1,436,080	\$	1,599,705	\$	163,626	10.2%	
Total Interest & Depreciation Expenses	\$	424,702	\$		\$	32,803	7.2%		2,161,269	\$	2,324,893	\$	163,624	7.0%	
Net Income (Loss) from Operations	<del>`</del>	186,225				<u> </u>	76.0%				1,086,071				
` , .	ş	186,225	\$	//4,386	\$	(588,161)	76.0%	Þ	4,537,927	\$	1,086,071	\$	3,451,856	317.8%	
Non-Operating Revenue/(Expenses)															
Tax Revenue	\$	87,659	\$		\$			Œ						36.2%	
			- :			5,159	6.3%	•	551,489	\$	405,000	\$	146,489		
Misc Revenue/(Expenses)	\$	85,470		69,250	\$	16,221	23.4%	\$	441,148	\$	357,182	\$	83,966	23.5%	
Total Non-Operating Rev/(Expenses)				69,250				\$		\$		\$			
Total Non-Operating Rev/(Expenses)  Net Income (Loss)	\$ \$	85,470 173,129 359,355	\$	69,250 151,750 926,136	\$ \$ \$	16,221 21,380 (566,781)	23.4% 14.1% 61.2%	\$ \$	441,148 992,637 5,530,564	\$ \$ \$	357,182 <b>762,182</b> <b>1,848,253</b>	\$ \$ \$	83,966 <b>230,455</b> <b>3,682,311</b>	23.5% 30.2% 199.2%	
Total Non-Operating Rev/(Expenses)	\$	85,470 <b>173,129</b>	\$	69,250 <b>151,750</b>	\$	16,221 <b>21,380</b>	23.4% <b>14.1%</b>	\$ \$	441,148 <b>992,637</b>	\$	357,182 <b>762,182</b>	\$	83,966 <b>230,455</b>	23.5% <b>30.2%</b>	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF	\$ \$	85,470 173,129 359,355	\$	69,250 151,750 926,136	\$ \$ \$	16,221 21,380 (566,781)	23.4% 14.1% 61.2%	\$ \$	441,148 992,637 5,530,564	\$ \$ \$	357,182 <b>762,182</b> <b>1,848,253</b>	\$ \$ \$	83,966 <b>230,455</b> <b>3,682,311</b>	23.5% 30.2% 199.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS	\$ \$	85,470 173,129 359,355 359,355	\$ \$ \$	69,250 151,750 926,136 926,136	\$ \$ \$	16,221 21,380 (566,781) (566,781)	23.4% 14.1% 61.2% 61.2%	\$ \$	441,148 992,637 5,530,564 5,530,564	\$ \$ \$	357,182 <b>762,182</b> 1,848,253 1,848,253	\$ \$ \$	83,966 230,455 3,682,311 3,682,311	23.5% 30.2% 199.2% 199.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin	\$ \$	85,470 173,129 359,355 359,355	\$ \$	69,250 151,750 926,136 926,136	\$ \$ \$	16,221 21,380 (566,781) (566,781)	23.4% 14.1% 61.2% 61.2% (45.9%)	\$ \$	441,148 992,637 5,530,564 5,530,564	\$ \$ \$	357,182 762,182 1,848,253 1,848,253	\$ \$ \$	83,966 230,455 3,682,311 3,682,311	23.5% 30.2% 199.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin  Operating Margin	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3%	23.5% 30.2% 199.2% 199.2% 80.0%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4%	\$ \$	69,250 151,750 926,136 926,136	\$ \$ \$	16,221 21,380 (566,781) (566,781)	23.4% 14.1% 61.2% 61.2% (45.9%)	\$ \$	441,148 992,637 5,530,564 5,530,564	\$ \$ \$	357,182 762,182 1,848,253 1,848,253	\$ \$ \$	83,966 230,455 3,682,311 3,682,311	23.5% 30.2% 199.2% 199.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3%	23.5% 30.2% 199.2% 199.2% 80.0%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9%	23.5% 30.2% 199.2% 199.2% 80.0%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction %	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9%	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR %	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2%	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction %	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9%	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR %	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2%	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss)  Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR % Net Operating Revenue %	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8% 45.5%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0% 56.2% 43.8% 45.8%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.2%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%) (0.5%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0% 47.4%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8% 47.1%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2% 0.2% 0.3%	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5% 0.6%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss) Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR % Net Operating Revenue %  Benefits as a % Of SW Benefits as a % of SWB	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8% 45.5% 25.8% 20.5%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0% 56.2% 43.8% 45.8% 20.5%	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%) (0.5%) (0.2%) (0.1%)	\$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0% 47.4% 26.1% 20.7%	\$ \$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8% 47.1% 25.8% 20.5%	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2% 0.3% (0.3%) (0.2%)	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5% 0.6% (1.4%) (1.1%)	
Total Non-Operating Rev/(Expenses)  Net Income (Loss) Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR % Net Operating Revenue %  Benefits as a % Of SW Benefits as a % of SWB  Paid FTEs (excludes Agency)	\$ \$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8% 45.5% 20.5% 294.2	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0% 56.2% 43.8% 45.8% 25.8% 20.5% 374.2	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 79.9	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%) (0.5%) (0.2%) (0.1%) 21.4%	\$ \$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0% 47.4% 26.1% 20.7% 296.42	\$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8% 47.1% 25.8% 20.5% 371.1	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2% 0.3% (0.3%) (0.2%) 74.7	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5% 0.6% (1.4%) (1.1%) 20.1%	
Total Non-Operating Rev/(Expenses)  Net Income (Loss) Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR % Net Operating Revenue %  Benefits as a % Of SW Benefits as a % of SWB	\$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8% 45.5% 25.8% 20.5%	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0% 56.2% 43.8% 45.8% 25.8% 20.5% 374.2 7,338	\$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%) (0.5%) (0.2%) (0.1%)	\$ \$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0% 47.4% 26.1% 20.7% 296.42 38,139	\$ \$	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8% 47.1% 25.8% 20.5% 371.1 36,254	\$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2% 0.3% (0.3%) (0.2%) 74.7 (1,885)	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5% 0.6% (1.4%) (1.1%)	
Total Non-Operating Rev/(Expenses)  Net Income (Loss) Net Income (Loss) w/out PPP+PRF  METRICS  EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH  Deduction % NPSR % Net Operating Revenue % Benefits as a % Of SW Benefits as a % of SWB  Paid FTEs (excludes Agency) Salary per FTE	\$ \$ \$	85,470 173,129 359,355 359,355 10.8% 3.3% 6.4% 52 289 56.2% 43.8% 45.5% 25.8% 20.5% 294.2 7,623	\$ \$	69,250 151,750 926,136 926,136 20.0% 12.6% 15.0% 56.2% 43.8% 45.8% 25.8% 20.5% 374.2	\$ \$ \$ \$	16,221 21,380 (566,781) (566,781) (9.2%) (9.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 79.9	23.4% 14.1% 61.2% 61.2% (45.9%) (73.8%) (57.7%) (0.0%) (0.1%) (0.5%) (0.2%) (0.1%) 21.4% (3.9%)	\$ \$ \$ \$	441,148 992,637 5,530,564 5,530,564 22.6% 15.3% 18.7% 55.0% 45.0% 47.4% 26.1% 20.7% 296.42	\$ <b>\$ \$ \$</b>	357,182 762,182 1,848,253 1,848,253 12.6% 4.0% 6.8% 55.2% 44.8% 47.1% 25.8% 20.5% 371.1	\$ \$ \$ \$	83,966 230,455 3,682,311 3,682,311 10.1% 11.3% 11.9% 0.2% 0.2% 0.3% (0.3%) (0.2%) 74.7	23.5% 30.2% 199.2% 199.2% 80.0% 174.2%  0.4% 0.5% 0.6% (1.4%) (1.1%) 20.1% (5.2%)	



# **Balance Sheet as of May 2022**

ASSETS	5/31/2022	4/30/2022	1 Month Variance	04/31/2021	12 Month Variance
Current Assets Operating Cash Covid Cares Restricted Debt Reserve	47,537,878 1,285,388 2,016,008	45,662,638 1,285,388 2,016,008	1,875,240 - -	38,579,911 - 2,016,008	8,957,967 1,285,388 -
Accounts Receivables Less Allow for Uncollectables Less Contractual Adjustments	21,542,271 (3,749,109) (9,519,897)	23,786,442 (3,751,491) (10,893,025)	(2,244,172) 2,382 1,373,128	16,255,736 (3,499,114) (6,999,895)	5,286,535 (249,995) (2,520,002)
Accounts Receivable - Net	8,273,265	9,141,926	(868,662)	5,756,727	2,516,538
Taxes Receivable Other Receivables Inventory Prepaid Expenses	103,920 1,439,784 749,461 577,432	427,772 1,972,468 766,166 578,364	(323,853) (532,685) (16,704) (932)	115,320 1,309,550 534,574 553,031	(11,400) 130,233 214,887 24,401
Total Current Assets	61,983,135	61,850,730	132,405	48,865,121	13,118,013
Property, Plant and Equipment Land Land Improvements Buildings Equipment Construction In Progress Less Accumulated Depreciation Property, Plant and Equipment - Net	1,652,029 4,440,695 43,842,103 14,541,886 1,628,046 (25,572,081) <b>40,532,678</b>	1,652,029 4,440,695 43,842,103 14,541,886 1,524,876 (25,291,236) <b>40,710,353</b>	- - - - 103,170 (280,845) (177,675)	1,652,029 4,407,786 43,373,790 11,792,487 73,151 (22,182,932) <b>39,116,310</b>	32,910 468,313 2,749,399 1,554,895 (3,389,149) <b>1,416,367</b>
TOTAL ASSETS	102,515,813	102,561,084	(45,271)	87,981,432	14,534,381




# **Balance Sheet as of May 2022**

LIABILITIES	05/31/2022	04/30/2022	1 Month Variance	04/31/2021	12 Month Variance
Current Liabilities					
Accounts Payable	1,940,597	1,916,429	24,168	360,233	1,580,363
Other Payables	358,893	763,208	(404,315)	210,748	148,145
Payroll and Related Liabilities	2,737,389	2,348,829	388,560	2,479,194	(29,297)
Interest Payable	44,761	(4,091)	48,852	94,967	(50,206)
Third Party Settlement Payable	(356,363)	69,327	(425,690)	203,525	(559,887)
Other Current Liabilities	1,719,391	1,711,354	8,036	5,201,029	(3,481,638)
Current Maturities of LTD	1,192,955	1,192,955	-	1,192,955	-
Total Current Liabilities	7,637,621	7,998,010	(360,389)	9,742,650	(2,392,520)
Non Current Liabilities					
Current Maturities of LTD	(1,192,955)	(1,192,955)	-	(1,192,955)	-
Long Term Debt	46,615,272	46,659,509	(44,237)	52,434,453	(5,819,181)
Total Non Current Liabilities	45,422,317	45,466,554	(44,237)	51,241,498	(5,819,181)
Total Liabilities	53,059,938	53,464,564	(404,626)	60,984,148	(8,211,701)
Net Assets					
Unrestricted Fund Balance	43,925,310	43,925,310	-	23,192,257	20,733,054
YTD Excess of Revenues	5,530,564	5,171,209	359,355	3,805,028	2,013,028
Total Net Assets	49,455,874	49,096,520	359,355	26,997,284	22,746,082
TOTAL LIABILITIES & NET ASSETS	102,515,813	102,561,084	(45,271)	87,981,432	14,534,381


INFORMATION   1.00	2022	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ост	NOV	DEC	
PRINCE NAME 179 146 135 25 125 125 125 125 125 125 125 125 125	INPATIENT STATISTICS	2.5	4.5			•								100
PARIED NAME   177							37	20	20	31	37	3∩	29	
MONE   146   77							- 07	20	20			30	2/	
PRINTED CHICAGO   18														
PRICE   4   27   27   27   28   33   44   37   27   27   33   44   37   27   27   37   37   37   37   37							144	109	122	110	129	85	105	
MORE   3.5   3.8   3.8   3.8   3.8   3.4   4.0   3.8   5.5   6.1   3.5   5.5   7.8   7.8   7.2   3.2   7.2			-				37	20	19	30	37	30	29	
COMMINISTATION   1.625   1.425   1.277   1.277   1.207   1.2														
OBSENTATION   1987		3.5	3.9	3.9	3.4	4.0	3.9	5.5	6.1	3.5	3.5	2.8	3.2	3.7
DISSEMENDIN STATE   17		751	1,428	1,892	1,219	1,302								6,592
## PECR   22   11   22   22   32   22   21   12   21   15   12   15   15							1,039	1,086	643	786	467	396	729	
SMESCHOPT VISITS   1433							٥٢	07	1.5	01	1.5	10	1/	
SUCCET 1.153 9-67 1.190 9-57 1.190 1.207 1.427 1.411 1.469 1.444 1.445 1.475 1.437 1.325 1.335 1.4016							25	26	15	21	15	12	16	
## AMC CLINIC VISITS   38] ## 505   748   770   772		1,153	947	1,190	1,269	,	,		1,444		1,437	1,375		6,016
## PICKET   902   673   1,065   745   757   526   757   1,056   711   777   796   796   797   359   713   4,099   7985 CUNC****   140							1,423	1,443	1,461	1,474	1,450	1,350	1,321	
PROC   741   725   599   805   796   798   801   704   807   777   805   713   4.099   798   801   704   807   777   805   713   4.099   798   801   704   807   777   805   713   4.099   798   801   704   807   777   777   805   713   4.099   798   801   704   807   777   777   805   713   713   713   713   713   714   715   7							1 036	911	797	986	890	1 015	813	
BIRCHOT	PRIOR			939										
PRINCE   161   177   48   80   66   49   56   55   105   127   127   59   312							110	00.4	200	2//	00.4	00.4	00.4	
SPANT CLINIC VISITS														
PRINCE   1935   2335   2337   238   2377   2386   1860   2244   2378   1900   1908   207   197   233   1342   13435   13457   13458   13458	SPMAT CLINIC VISITS	184	180	205	188	195						·		952
SPINC CLINIC VISITS														
BUDCEL PROPE							224	218	190	198	207	192	233	
ALI CLINIC VISITS 4,110 3,947 4,387 3,871 3,382		_			_		2,906	2,969	2,932	3,079	3,083	3,125	3,131	
BUDICICE    3,607   3,997   3,816   3,784   3,786   4,287   4,232   4,241   4,677   4,485   4,897   3,942   118,323     PACC CLINIC VISITS   4   5   6   1   1   1   0   0.075   4,305   4,119   4,305   3,119   3,942   118,323     PACC CLINIC VISITS   4   5   6   1   1   1   0   0.075   4,305   4,119   4,305   3,116   3,942   118,323     PROCE   4   7   7   7   7   2   5   5   7   14   9   4   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   9   4   2   2   2.88     PROCE   5   7   14   1   2   2   2   2   2   2   2   2   2				_			2,981	2,986	3,376	3,066	3,364	3,165	3,053	
PHONE   3.06   3.279   4.067   3.711   3.650   4.170   4.073   4.308   4.171   4.586   3.716   3.842   13.32   17.7   PROC   1.06   1.06   1.06   1.06   1.16   1							4.287	4,332	4.241	4.627	4.465	4.639	4.385	
PRIOR   6														
BUDGET   BOB   BIT   SPT   1.1194   1.1294   1.209   1.376   1.306   1.324   1.166   1.274   1.202   5.141   PRIOR   BOB   BIT   SPT   1.119   1.134   1.229   1.376   1.306   1.333   1.164   1.249   1.275   5.234   PRIOR   BOB   BIT   SPT   1.119   1.1414   1.352   1.233   1.362   1.806   1.333   1.164   1.246   1.175   5.234   PRIOR   BOB   BIT   SPT   1.1096   1.112   1.155   1.327   1.201   1.813   1.336   1.177   1.276   1.202   5.141   1.201							,	-	7	1.4	0	4	0	
BUDGET   968   817   997   1.119   1.340   1.209   1.376   1.800   1.324   1.168   1.274   1.202   5.141   PRIOR   993   893   897   1.016   1.144   1.325   1.233   1.816   1.233   1.184   1.286   1.715   5.234   PACC+ URGENT CARE VISITS   1.210   1.048   1.112   1.155   1.372   1.321   1.811   1.333   1.187   1.262   1.175   5.234   1.205					,		6	5	/	14	9	4	2	
PACC + URGENT CARE WISTS   1,210		868	817	997		1,340	1,209	1,376		1,324		1,274	1,202	5,141
BUDGET 874 821 1.006 1.126 1.342 1.215 1.381 1.813 1.336 1.177 1.278 1.204 5.149 PRIOR 879 833 1.025 1.151 1.354 1.239 1.347 1.815 1.347 1.173 1.226 1.177 5.242 ANGULARY STATISTICS  ANGULARY STATISTICS  ANGULARY STATISTICS  ANGULARY STATISTICS  BUDGET 15.113 13.348 15.866 15.014 15.551 16.437 15.750 15.753 15.200 16.055 16.051 14.870 74.873 PRIOR 14.805 13.376 15.343 14.708 15.524 16.009 15.605 15.432 15.200 15.055 16.051 14.870 74.873 PRIOR 14.805 13.376 15.431 14.00 15.524 16.102 15.605 15.402 15.757 15.724 15.724 15.724 15.724 15.724 15.724 15.724 15.724 15.724 15.725 15.724 15.72							1,233	1,362	1,808	1,333	1,184	1,248	1,175	
PRIOR   89   833   1,025   1,151   1,354   1,239   1,367   1,815   1,347   1,193   1,252   1,177   5,242		_	_				1.215	1.381	1.813	1.338	1.177	1.278	1.204	
MABBURDER    15,776											,		_	
BUDGET 15.113 13.348 15.866 15.014 15.551 16.437 15.930 15.733 15.520 16.005 16.005 14.870 74.893 PRIOR 14.805 13.076 15.543 14.708 15.234 16.102 15.005 14.23 15.204 16.005 16.005 14.870 73.346 ALIXRAY EXAMS 1.371 1.391 1.495 13.390 1.553		15 27/	14.5/1	17,000	15 052	17.040								70 121
PRICOR   14,805   13,076   15,543   14,708   15,244   16,102   15,635   15,032   15,204   15,724   14,867   73,346   14,104   14,107   1,102   1,366   1,348   1,330   1,333   1,448   1,287   1,451   1,341   1,499   1,398   1,312   6,348   1,448   1,287   1,451   1,431   1,379   1,379   1,379   1,244   6,242   X8AY EXAMS   1,145   1,142   1,244   1,207   1,338   1,478   1,168   1,077   1,202   1,111   1,242   1,177   1,105   5,298   1,451   1,454   1,477   1,104   1,148   1,192   1,168   1,077   1,202   1,111   1,242   1,177   1,103   5,298   1,451							16,437	15,930	15,753	15,520	16,065	16,051	14,870	
BUDGET 1,177 1,102 1,366 1,348 1,354 1,448 1,287 1,451 1,341 1,499 1,398 1,312 6,348 PRICOR 1,161 1,087 1,348 1,330 1,333 1,320 1,270 1,431 1,323 1,479 1,379 1,274 6,262 XKAY KEAMS 1,145 1,142 1,147 1,120 1,348 1,330 1,333 1,428 1,270 1,431 1,323 1,479 1,379 1,274 6,262 XKAY KEAMS 1,145 1,145 1,142 1,144 1,120 1,338 1,479 1,70 1,202 1,111 1,242 1,177 1,130 5,278 MAMMO EXAMS 1,77 1,99 1,97 1,48 1,170 1,106 1,177 1,202 1,111 1,242 1,177 1,130 5,278 MAMMO EXAMS 1,77 1,99 1,97 1,48 1,170 1,100 1,111 1,242 1,177 1,130 5,278 MAMMO EXAMS 4,9 50 54 33 1,24 2,12 1,179 1,180 1,170 1,180 1,170 1,180 1,170 1,18				15,543		15,234	16,102	15,605			15,737	15,724	14,567	
PRIOR							1 440	1 007	1 451	1 241	1 400	1 200	1 210	
XRAY EXAMS														
MAMMO EXAMS							11/0	1.077	1.000		1.0.40	, , , , , ,	1 100	
PRIOR							1,168	1,077	1,202	1,111	1,242	1,1//	1,130	
FRIOR							212	159	182	178	195	169	130	
CTEXAMS														
BUDGET							48	34	4/	34	42	33	34	
ALL UITRASOUND EXAMS  BUDGET  309  316  337  338  338  338  338  338  338  33							529	542	524	486	555	520	478	
BUDGET 309 316 357 342 338 383 385 390 330 412 355 337 1,662 PRIOR 304 311 352 337 333 377 379 384 325 406 350 332 1,637 UITRASOUND EXAMS 344 313 372 325 321							492	504	487	452	516	483	444	· · · · ·
PRIOR							383	385	390	330	412	355	337	
PRIOR 265 274 309 302 289 328 327 332 301 349 299 290 1,439 ECHO EXAMS 45 51 61 65 64						333								
ECHO EXAMS							200	207	220	201	2.40	000	2000	
PRIOR   39   37   43   35   44   49   52   52   24   57   51   42   198							320	32/	332	301	349	299	290	
BUDGET   98   87   108   108   87   101   87   131   114   84   107   35   490     PRIOR   56   50   62   62   50   58   50   75   65   48   61   20   280     THERAPY EXAMS   709   625   790   862   888	PRIOR	39	37	43	35	44	49	52	52	24	57	51	42	198
PRIOR							101	0.7	101	114	0.4	107	25	
THERAPY EXAMS   709   625   790   862   888														
PRIOR	THERAPY EXAMS	709	625	790	862	888								3,874
PT EXAMS-OUTPATIENT														
PT EXAMS-INPATIENT   17							042	721	001	774	940	760	700	
OT EXAMS-INPATIENT   12   7   4   14   12	PT EXAMS-INPATIENT	17	12	7	18	16								70
ST EXAMS-OUTPATIENT														
ST EXAMS-INPATIENT														
DAYS IN AR         57         56         60         56         52         S2         S5         S6         S6         S6         S2         S5         S5         S6         S6         S6         S2         S5         S5         S6         S7         S7         S7         S7         S7         S7         S7         S7         S9	ST EXAMS-INPATIENT		-	-										
GOAL         47         4		£7	EL	40	EL	52								E /
PRIOR         53         54         52         47         49         52         57         52         58         59         59         59         59           DAYS CASH ON HAND         323         328         307         281         289         8         9         59         59         59         59         59           GOAL         260							47	47	47	47	47	47	47	
GOAL         260 <td>PRIOR</td> <td>53</td> <td>54</td> <td>52</td> <td>47</td> <td>49</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>59</td>	PRIOR	53	54	52	47	49								59
PRIOR         255         256         262         254         259         257         249         249         245         241         269         293         257           FTES TOTAL PAID         285.5         303.4         305.1         293.9         294.2         294.2         296.4         296.4         296.4         296.4         297.8         310.0         322.3         317.1         317.1         -							240	240	240	240	240	240	240	
FTES TOTAL PAID         285.5         303.4         305.1         293.9         294.2         294.2         296.4           FTES TOTAL INCLUDING AGENCY         297.8         310.0         322.3         317.1         317.1         -         <														
BUDGET 370.4 370.4 370.4 370.4 374.2 374.2 376.2 376.2 376.2 376.2 376.2 376.2 376.2 376.2 376.2 376.2 376.2	FTEs TOTAL PAID	285.5	303.4	305.1	293.9	294.2								296.4
							374.2	376.2	376.2	374.0	- 374.2	376.2	376.2	




### Volume Dashboards































### Finance Dashboards

